APUS (Apimeds Pharmaceuticals Us) Stock Based Compensation: $11.49 Mil (TTM As of Mar. 2026)


APUS Apimeds Pharmaceuticals Us Inc APUS
14 GF Score
Price $0.72
! 3 Warning Signs
View Full Analysis

What is Apimeds Pharmaceuticals Us Stock Based Compensation?

Apimeds Pharmaceuticals Us APUS -2.04% 14 Stock Based Compensation is $11.49 Mil as of Mar. 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Apimeds Pharmaceuticals Us's Stock Based Compensation for the three months ended in Mar. 2026 was $8.23 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $11.49 Mil.

Apimeds Pharmaceuticals Us Stock Based Compensation Related Terms

Apimeds Pharmaceuticals Us Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Apimeds Pharmaceuticals Us's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apimeds Pharmaceuticals Us Stock Based Compensation Chart

Apimeds Pharmaceuticals Us Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.19 0.19 0.07 0.00 3.27

Apimeds Pharmaceuticals Us Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.89 0.04 1.33 8.23
APUS
14GF Score
Apimeds Pharmaceuticals Us Inc APUS
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apimeds Pharmaceuticals Us Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.49 Mil.

What does a Stock Based Compensation of $11.49 Mil mean?
Apimeds Pharmaceuticals Us (APUS) has a Stock Based Compensation of $11.49 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Apimeds Pharmaceuticals Us and its competitors.
Is Apimeds Pharmaceuticals Us' Stock Based Compensation too high?
Apimeds Pharmaceuticals Us' current Stock Based Compensation is $11.49 Mil. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' Stock Based Compensation compare to KAYS and BIOE?
Apimeds Pharmaceuticals Us' Stock Based Compensation of $11.49 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Apimeds Pharmaceuticals Us and its competitors. Apimeds Pharmaceuticals Us's current Stock Based Compensation is $11.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current Stock Based Compensation of $11.49 Mil. The current Stock Based Compensation is $11.49 Mil. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current Stock Based Compensation is $11.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apimeds Pharmaceuticals Us Business Description

Address 100 Matawan Road, Suite 325, Matawan, NJ, USA, 07747
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score

Get the complete analysis for APUS

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price